A share price of Rigel Pharmaceuticals [RIGL] is currently trading at $24.39, up 6.79%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RIGL shares have gain 7.92% over the last week, with a monthly amount glided 46.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citigroup downgraded its rating to Neutral on June 09, 2022. On June 08, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $1 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral and decreased its price target to $1 on June 08, 2022. B. Riley Securities initiated its recommendation with a Neutral and recommended $4 as its price target on March 23, 2022. JP Morgan downgraded its rating to Neutral for this stock on November 09, 2020.
Rigel Pharmaceuticals experienced fluctuations in its stock price throughout the past year between $7.48 and $29.82. Currently, Wall Street analysts expect the stock to reach $1.5 within the next 12 months. Rigel Pharmaceuticals [NASDAQ: RIGL] shares were valued at $24.39 at the most recent close of the market. An investor can expect a potential drop of -93.85% based on the average RIGL price forecast.
Analyzing the RIGL fundamentals
Trailing Twelve Months sales for Rigel Pharmaceuticals [NASDAQ:RIGL] were 157.47M which represents 96.58% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is -0.15 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-4.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.50 points at the first support level, and at 22.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.88, and for the 2nd resistance point, it is at 25.38.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Rigel Pharmaceuticals [NASDAQ:RIGL] is 1.96. In addition, the Quick Ratio stands at 1.81 and the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 2.73 and price to earnings (TTM) ratio is 112.60.
Transactions by insiders
Recent insider trading involved Schorno Dean L, EVP & Chief Financial Officer, that happened on Feb 04 ’25 when 2036.0 shares were sold. EVP & Chief Financial Officer, Schorno Dean L completed a deal on Feb 05 ’25 to sell 1734.0 shares. Meanwhile, EVP, Chief Commercial Officer Santos David A sold 2125.0 shares on Feb 04 ’25.
